Pramipexole, a Dopamine Agonist, in Major Depression: Antidepressant Effects and Tolerability in an Open-Label Study with Multiple Doses
The DOI matches its Crossref record.
Abstract
Summary: The safety, tolerability, and the antidepressant effects of pramipexole, a dopaminergic agonist, were assessed in 26 patients hospitalized for major depression. Total daily doses ranged from 1.75 to 9.0 mg using a 14-day dose escalation phase to reach the target or highest attainable dose, which was then administered unchanged for an additional 14 days. The study was terminated at the 6.25-mg dose level because nausea, restlessness, headache, and insomnia became dose-limiting. No clinically important laboratory, electrocardiographic, or vital sign abnormalities were noted. Ninety-six percent of the patients (25/26) were markedly or severely ill by the Clinical Global Impression severity scale at the start of the study, whereas only 27% (7/26) remained in this category at the final visit. Pramipexole administration resulted in consistent reductions in clinical depression. Scores on three major rating scales showed reductions of ≥35% in 13, 12, and 10 of the 26 patients, respectively. A more marked improvement of at least 50% was also noted in a substantial number of patients (MADRS 9/26, BRMES 7/26, and HAMD-17 6/26). This escalating dose-tolerance study with preliminary efficacy data demonstrated sufficient safety and antidepressant properties of pramipexole in severely depressed patients to justify a larger doubleblind, placebo-controlled trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Clinical Presentation of the “Depression–Executive Dysfunction Syndrome” of Late Life
Alexopoulos, G. S., Kiosses, D. N., Klimstra, S., Kalayam, B., & Bruce, M. L. (2002) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200201000-00012 · Cited by 361
Rektorová, I., Rektor, I., Bareš, M., Dostál, V., Ehler, E., Fanfrdlová, Z., Fiedler, J., Klajblová, H., Kulišt’ák, P., Ressner, P., et al. (2003) · European Journal of Neurology · doi:10.1046/j.1468-1331.2003.00612.x · Cited by 253
Burn, D. J. (2002) · Movement Disorders · doi:10.1002/mds.10114 · Cited by 223
Management of behavioral and psychiatric problems in Parkinson's disease
Rabinstein, A. A., & Shulman, L. M. (2000) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(00)00039-0 · Cited by 30
Metadata
- Authors
- Szegedi, A., Hillert, A., Wetzel, H., Klieser, E., Gaebel, W., & Benkert, O.
- Venue
- Clinical Neuropharmacology
- Published
- 1997
- Volume
- 20
- Pages
- S36-S45
- ISSN
- 0362-5664 (ISSN-L)
- OpenAlex
- W2330280326
- Cited by
- 47
- References
- 0
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pramipexole, a Dopamine Agonist, in Major Depression: Antidepressant Effects and Tolerability in an Open-Label Study with Multiple Doses. https://app.cochat.ai/papers/10.1097/00002826-199720001-00006
- The paper
- Szegedi, A., Hillert, A., Wetzel, H., Klieser, E., Gaebel, W., & Benkert, O. (1997). Pramipexole, a Dopamine Agonist, in Major Depression: Antidepressant Effects and Tolerability in an Open-Label Study with Multiple Doses. Clinical Neuropharmacology. https://doi.org/10.1097/00002826-199720001-00006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.